US 12,421,275 B2
Compositions and methods for treating CNS disorders
Albert Jean Robichaud, Boston, MA (US); Francesco G. Salituro, Marlborough, MA (US); Maria Jesus Blanco-Pillado, Arlington, MA (US); Daniel La, Chestnut Hill, MA (US); and Boyd L. Harrison, Princeton Junction, NJ (US)
Assigned to Sage Therapeutics, Inc., Cambridge, MA (US)
Filed by Sage Therapeutics, Inc., Cambridge, MA (US)
Filed on Jun. 5, 2023, as Appl. No. 18/328,865.
Application 18/328,865 is a division of application No. 16/961,097, granted, now 11,718,642, previously published as PCT/US2019/013315, filed on Jan. 11, 2019.
Claims priority of provisional application 62/728,514, filed on Sep. 7, 2018.
Claims priority of provisional application 62/617,134, filed on Jan. 12, 2018.
Claims priority of provisional application 62/616,768, filed on Jan. 12, 2018.
Prior Publication US 2024/0150393 A1, May 9, 2024
Int. Cl. A61K 31/58 (2006.01); A61P 25/00 (2006.01); C07J 73/00 (2006.01)
CPC C07J 73/003 (2013.01) 28 Claims
 
1. A compound of Formula (I-III)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein
m is 0, 1, or 2;
X is —O—;
R3a is unsubstituted C1-6 alkyl or C1-6 alkyl substituted with C1-6 alkoxy;
R5 is hydrogen or methyl;
R1 is substituted or unsubstituted C1-6 alkyl or substituted or unsubstituted heteroaryl; and
each of R1a, R1b, R2a, R2b, R4a, R4b, R7a, R7b, R11a, R11b, R12a, R12b, R15a, R15b, R16a, and R16b is hydrogen.